- Home
- LSF vs AGEN Comparison
LSF vs AGEN Comparison
Compare LSF & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- AGEN
- Stock Information
- Founded
- LSF 2015
- AGEN 1994
- Country
- LSF United States
- AGEN United States
- Employees
- LSF N/A
- AGEN N/A
- Industry
- LSF Packaged Foods
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LSF Consumer Staples
- AGEN Health Care
- Exchange
- LSF Nasdaq
- AGEN Nasdaq
- Market Cap
- LSF 62.0M
- AGEN 123.6M
- IPO Year
- LSF 2020
- AGEN 2000
- Fundamental
- Price
- LSF $4.80
- AGEN $4.09
- Analyst Decision
- LSF Strong Buy
- AGEN Buy
- Analyst Count
- LSF 2
- AGEN 2
- Target Price
- LSF $12.00
- AGEN $14.50
- AVG Volume (30 Days)
- LSF 31.6K
- AGEN 469.6K
- Earning Date
- LSF 11-10-2025
- AGEN 11-11-2025
- Dividend Yield
- LSF N/A
- AGEN N/A
- EPS Growth
- LSF N/A
- AGEN N/A
- EPS
- LSF N/A
- AGEN N/A
- Revenue
- LSF $47,027,546.00
- AGEN $101,706,000.00
- Revenue This Year
- LSF $21.88
- AGEN $60.49
- Revenue Next Year
- LSF $20.86
- AGEN N/A
- P/E Ratio
- LSF N/A
- AGEN N/A
- Revenue Growth
- LSF 22.79
- AGEN N/A
- 52 Week Low
- LSF $4.45
- AGEN $1.38
- 52 Week High
- LSF $10.90
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- LSF 37.43
- AGEN 46.47
- Support Level
- LSF $4.70
- AGEN $3.77
- Resistance Level
- LSF $5.35
- AGEN $4.60
- Average True Range (ATR)
- LSF 0.32
- AGEN 0.24
- MACD
- LSF -0.03
- AGEN 0.00
- Stochastic Oscillator
- LSF 27.65
- AGEN 32.53
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).